[Code of Federal Regulations] [Title 21, Volume 7] [Revised as of April 1, 2008] From the U.S. Government Printing Office via GPO Access [CITE: 21CFR660.55] [Page 130-131] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) PART 660_ADDITIONAL STANDARDS FOR DIAGNOSTIC SUBSTANCES FOR LABORATORY TESTS-- Subpart F_Anti-Human Globulin Sec. 660.55 Labeling. In addition to the applicable labeling requirements of Sec. Sec. 610.62 through 610.65 and Sec. 809.10 of this chapter, and in lieu of the requirements in Sec. Sec. 610.60 and 610.61 of this chapter, the following requirements shall be met: (a) Final container label--(1) Color coding. The main panel of the final container label of all Anti-IgG, -C3d (polyspecific) reagents shall be white or colorless and printing shall be solid dark contrasting lettering. The main panel of the final container label of all other Anti-Human Globulin reagents shall be black with solid white lettering. A logo or company name may be placed on the final container label, however, the logo or company name shall be located along the bottom or end of the label, outside of the main panel. (2) Required information. The proper name ``Anti-Human Globulin'' need not appear on the final container label provided the final container is distributed in a package and the package label bears the proper name. The final container label shall bear the following information: (i) Name of the antibody or antibodies present as set forth in paragraph (d) of this section. Anti-Human Globulin may contain one or more antibodies to either immunoglobulins or complement components but the name of each significant antibody must appear on the final container label (e.g., anti-C3b, -C3d, -C4d). The final container labels of polyspecific Anti-Human Globulin are not required to identify antibody specificities other than anti-IgG and anti-C3d but the reactivity of the Anti-Human Globulin shall be accurately described in the package insert. (ii) Name, address, and license number of the manufacturer. [[Page 131]] (iii) Lot number, including any sublot designations. (iv) Expiration date. (v) Source of the product. (vi) Recommended storage temperature in degrees Celsius. (vii) Volume of product. (viii) Appropriate cautionary statement if the Anti-Human Globulin is not polyspecific. For example, ``DOES NOT CONTAIN ANTIBODIES TO IMMUNOGLOBULINS'' or ``DOES NOT CONTAIN ANTIBODIES TO COMPLEMENT COMPONENTS.'' (ix) If the final container is not enclosed in a package, all items required for a package label shall appear on the container label. (3) Lettering size. The type size for the designation of the specific antibody on the label of a final container shall be not less than 12 point, unless otherwise approved by the Director, Center for Biologics Evaluation and Research. The prefix anti- and other parts of the name such as polyspecific may appear in smaller type. (4) Visual inspection. When the label has been affixed to the final container, a sufficient area of the container shall remain uncovered for its full length or for no less than 5 millimeters of the lower circumference to permit inspection of the contents. (b) Package label. The following items shall appear either on the package label or on the final container label if see-through packaging is used: (1) Proper name of the product, and the name of the antibody or antibodies as listed in paragraph (d) of this section. (2) Name, address (including zip code), and license number of the manufacturer. (3) Lot number, including any sublot designations. (4) Expiration date. (5) Preservative(s) used and its concentration. (6) Number of containers, if more than one. (7) Recommended storage temperature in degrees Celsius. (8) Source of the product. (9) Reference to enclosed package insert. (10) The statement: ``For In Vitro Diagnostic Use.'' (11) The statement: ``Meets FDA Potency Requirements.'' (12) A statement of an observable indication of an alteration of the product, e.g., turbidity, color change, precipitate, that may indicate possible deterioration of the product. (13) Appropriate cautions. (c) Package insert. Each final container of Anti-Human Globulin shall be accompanied by a package insert meeting the requirements of Sec. 809.10 of this chapter. If two or more final containers requiring identical package inserts are placed in a single package, only one package insert per package is required. (d) Names of antibodies. ------------------------------------------------------------------------ Antibody designation on container label Definition ------------------------------------------------------------------------ (1) Anti-IgG, -C3d; Polyspecific...... Contains anti-IgG and anti-C3d (may contain other anticomplement and anti- immunoglobulin antibodies). (2) Anti-IgG.......................... Contains anti-IgG with no anti- complement activity (not necessarily gamma chain specific). (3) Anti-IgG; heavy chains............ Contains only antibodies reactive against human gamma chains. (4) Anti-C3b.......................... Contains only C3b antibodies with no anti-immunoglobulin activity. Note: The antibody produced in response to immunization is usually directed against the antigenic determinant which is located in the C3c subunit; some persons have called this antibody ``anti-C3c.'' In product labeling, this antibody should be designated anti-C3b. (5) Anti-C3d.......................... Contains only C3d antibodies with no anti-immunoglobulin activity. (6) Anti-C4b.......................... Contains only C4b antibodies with no anti-immunoglobulin activity. (7) Anti-C4d.......................... Contains only C4d antibodies with no anti-immunoglobulin activity. ------------------------------------------------------------------------ Anti-Human Globulin preparations may contain one or more of the antibody specificities listed in this paragraph as described in paragraph (a)(2)(i) of this section. [50 FR 5579, Feb. 11, 1985; 50 FR 9800, Mar. 12, 1985, as amended at 50 FR 16474, Apr. 26, 1985; 55 FR 11014, Mar. 26, 1990; 67 FR 9587, Mar. 4, 2002; 70 FR 14986, Mar. 24, 2005]